Marika Barbieri-Antonoglou

Discussion re: joint government/industry work on chemical and plastics in Canadian supply chains + development of joint consultation process. Discussion on policies and programs related to chemicals management, including the safe use, handling, and oversight of substances within the chemical and plastics industries, and their connection to sustainability and Responsible Care® practices. General introduction to the chemistry and plastics industries and their role in Canada’s economy and sustainability objectives. Advocating for CIAC’s pre-budget recommendations to strengthen investment attraction, advance climate policy, and improve plastics sector competitiveness. Addressed the impacts of rail labour disruptions on supply chain efficiency and overall industry performance. Environment, Health, and Industry policies related to plastics, in terms of providing input on the development and implementation of the Federal Plastics Registry and Recycled Content Requirement. Engaging on Canada’s participation in the Intergovernmental Negotiating Committee (INC) process on a global treaty to address plastic pollution, including impacts on the marine environment. International Trade Issues associated with cross border trade between Canada and the USA. This includes negotiations with the USA on the implementation of the Canada, US, Mexico Agreement (CUSMA) and other trade agreements. Impact of US Tariffs on Canadian industry. Communicating with public office holders to promote the industry cluster in Sarnia-Lambton and its long term sustainability Accelerated Capital Cost Allowance Program: making it permanent or extending it to align with Canada’s ITCs for emissions reduction. Water policy in terms of providing input on the impact of chemical manufacturing operations and the substances used/produced by the industry Transportation of Dangerous Goods Act: providing input related to the Transportation Code contained in the chemical industry's Responsible Care® Ethic and the safe management of chemicals in transport Scientific Research and Experimental Development (SR&ED) Tax Credit: providing input on its applicability to research in the chemical industry Occupational Health and Safety Workplace Hazardous Material Information System (WHMIS) and Globally Harmonized System (GHS): input on the impact of the chemical industry within the context of the Responsible Care® Ethic Impact of Carbon Pricing or emission intensity criteria on industry. Environmental Policy: input on chemical manufacturing operations and the substances produced and used by the industry Energy Policy: greater federal/provincial alignment on energy policies and streamlined environmental assessments for energy projects. Economic and Fiscal Policy: input on federal financial and tax issues Competition Act: impact of federal policies on the competitiveness of the Canadian chemical and plastic industries; Bill C-59 and amendments to greenwashing provisions. Concerns regarding climate change policies: impact of carbon pricing and emissions criteria on the industry. Climate Change Policy: input on federal federal strategies and processes to address greenhouse gas emissions Clean Air Regulatory Framework and Comprehensive Air Management System: Impact on the chemical and plastic industries. Chemical Industry Statistics: Data related to the chemical and plastic industries. Canadian Environmental Protection Act (CEPA): Application to substances produced or used in the chemical and plastic industries. Canadian Environmental Assessment Act and Regulations: impact on assessments of projects in the chemical and plastic industries. Canada Transportation Act: provisions related to railways and impact on the Canadian chemical and the plastic industries. Bill S-5 An Act to Amend the Canadian Environmental Protection Act 1999, to make related amendments to the Food and Drugs Act and to repeal the Perfluorooctane Sulfonate Virtual Elimination Act (CEPA Modernization). Key areas: changes to the

Postal service disruption and the significant hardships these disruptions cause for Canadians and on health charities We ask the federal government to fund MS research in partnership with MS Canada, leveraging our connections and expertise to focus and further our understanding of MS, pursue leading-edge research on repair and regeneration, and explore prevention strategies, including targeting the Epstein-Barr virus (EBV). Safe Long-Term Care Act with respect to persons affected by MS National Housing Strategy with respect for persons with MS and other chronic conditions and disabilities Measures and funding for the charitable sector generally Home care, with respect to creation with provincial/ territorial governments programs relating to increased home care for persons with MS and other disabilities/ diseases and the support of caregivers Federal Budget: Allocate funding for the Canada Disability Benefit, the Employment Insurance Sickness Benefit; health research; access to treatment and care; and other budgetary policy as it relates to MS. Establishment of national strategy for neurological conditions, with respect to persons with MS and other neurological conditions. Employment Insurance sickness benefits, with respect to creation of flexible benefits for persons with MS and other episodic disabilities Disability Tax Credit with respect to making it refundable and ensuring eligibility for Canadians with episodic disabilities Comprehensive disability income programs, with respect to persons with MS and other chronic and episodic disabilities CIHR as it relates to federal funding & long term investment in health research Canada Pension Plan – Disability with respect to eligibility for persons with MS and other chronic and episodic disabilities Canada Health Transfer - health system funding transfer and agreements intended for provinces/territories to support the delivery of healthcare services, including MS care Canada Health Act and regulations, as it relates to long-term and home care Bill C-64, An Act Respecting Pharmacare with respect for persons with MS and other chronic conditions and disabilities Access to treatments as it relates to the current regulatory and price negotiation processes to enhance timely access to all Health Canada approved MS disease-modifying therapies, with respect to the National Strategy for Drugs for Rare Diseases and national pharmacare.